Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 9/20 | 0.43 |
| ▸ | NOS2 | P35228 | 8/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | NOS3 | P29474 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | PNMT | P11086 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9446191 | 0.84 | SIGMAR1 (0.48) | SIGMAR1 | |
| SCHEMBL14196578 | 0.82 | L3MBTL1 (0.44) | NOS1NOS2NOS3ALDH1A1LOXL2 | |
| SCHEMBL9446203 | 0.81 | NOS1 (0.42) | NOS1NOS2MAP4K4 | |
| SCHEMBL28084794 | 0.80 | ALDH1A1 (0.46) | ENPP2NOS1NOS2NOS3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2464384 | 0.80 | NOS1 (0.47) | ENPP2NOS1NOS2PNMTL3MBTL1 | |
| SCHEMBL27522780 | 0.79 | NOS1 (0.44) | ENPP2NOS1NOS2ALDH1A1PNMT | |
| SCHEMBL303475 | 0.78 | ENPP2 (0.43) | ENPP2NOS1NOS2NOS3ALDH1A1 | |
| SCHEMBL348900 | 0.77 | ALDH1A1 (0.48) | ENPP2NOS1NOS2NOS3ALDH1A1 | |
| SCHEMBL31662833 | 0.77 | ALDH1A1 (0.48) | ENPP2NOS1NOS2NOS3ALDH1A1 | |
| SCHEMBL8095675 | 0.77 | HTR7 (0.47) | MAP4K4ALDH1A1CYP3A4L3MBTL1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294749-A1 | DIAMINOPYRIMIDINECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-12-01 | — | — | US | disclosed |
| EP-1518855-B1 | DIAMINOPYRIMIDINECARBOXA MIDE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-8012959-B2 | Diaminopyrimidinecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2011-09-06 | — | — | US | disclosed |
| US-20090281072-A1 | Diaminopyrimidinecarboxamide Derivative | ASTELLAS PHARM INC. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-7449456-B2 | Diaminopyrimidinecarboxamide derivative | ASTELLAS PHARMA, INC. (JP) | 2008-11-11 | — | — | US | disclosed |
| US-20050272753-A1 | Diaminopyrimidinecarboxa mide derivative | ASTELLAS PHARMA INC. (JP) | 2005-12-08 | — | — | US | disclosed |
| EP-1518855-A1 | DIAMINOPYRIMIDINECARBOXA MIDE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2005-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294749-A1 | DIAMINOPYRIMIDINECARBOXAMIDE DERIVATIVE | STAT6, STAT4, STAT3 | ENPP2 1138/4885NOS1 807/4885NOS2 534/4885 |
| US-20050272753-A1 | Diaminopyrimidinecarboxa mide derivative | STAT5A, STAT6, STAT4 | ENPP2 2150/4885NOS1 857/4885NOS2 693/4885 |
| US-20090281072-A1 | Diaminopyrimidinecarboxamide Derivative | STAT6, STAT4, STAT3 | ENPP2 1138/4885NOS1 807/4885NOS2 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.